- Home
- DLHC vs IKNA Comparison
DLHC vs IKNA Comparison
Compare DLHC & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLHC
- IKNA
- Stock Information
- Founded
- DLHC 1969
- IKNA 2016
- Country
- DLHC United States
- IKNA United States
- Employees
- DLHC N/A
- IKNA N/A
- Industry
- DLHC Business Services
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- DLHC Consumer Discretionary
- IKNA Health Care
- Exchange
- DLHC Nasdaq
- IKNA Nasdaq
- Market Cap
- DLHC 79.6M
- IKNA 63.7M
- IPO Year
- DLHC N/A
- IKNA 2021
- Fundamental
- Price
- DLHC $5.70
- IKNA $1.37
- Analyst Decision
- DLHC
- IKNA Strong Buy
- Analyst Count
- DLHC 0
- IKNA 1
- Target Price
- DLHC N/A
- IKNA $4.00
- AVG Volume (30 Days)
- DLHC 95.5K
- IKNA 63.1K
- Earning Date
- DLHC 07-30-2025
- IKNA 08-07-2025
- Dividend Yield
- DLHC N/A
- IKNA N/A
- EPS Growth
- DLHC 75.08
- IKNA N/A
- EPS
- DLHC 0.38
- IKNA N/A
- Revenue
- DLHC $377,074,000.00
- IKNA N/A
- Revenue This Year
- DLHC N/A
- IKNA N/A
- Revenue Next Year
- DLHC N/A
- IKNA N/A
- P/E Ratio
- DLHC $15.03
- IKNA N/A
- Revenue Growth
- DLHC N/A
- IKNA N/A
- 52 Week Low
- DLHC $2.72
- IKNA $0.97
- 52 Week High
- DLHC $11.99
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- DLHC 55.57
- IKNA 55.10
- Support Level
- DLHC $5.60
- IKNA $1.31
- Resistance Level
- DLHC $5.97
- IKNA $1.42
- Average True Range (ATR)
- DLHC 0.20
- IKNA 0.05
- MACD
- DLHC -0.04
- IKNA -0.00
- Stochastic Oscillator
- DLHC 46.77
- IKNA 51.24
About DLHC DLH Holdings Corp.
DLH Holdings Corp is a provider of technology-enabled business process outsourcing and program management solutions in the United States. The company offers services to several government agencies which include the Department of Veteran Affairs. The company is engaged in public health, performance evaluation, and health operations to solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, analytics, cloud-based applications, telehealth systems, and others.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.